Education
About Us
Working with TipRanks
Follow Us
Pulmonx Corporation (LUNG)
:LUNG
Earnings Data
Report Date
May 06, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.4Last Year’s EPS
-0.36Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 19, 2025
|% Change Since: -18.52%
|Next Earnings Date:May 06, 2025
Earnings Call Sentiment|Neutral
Pulmonx demonstrated strong revenue growth and international expansion, with significant advancements in clinical trials and product innovation. However, increased operating expenses and persistent net losses highlight ongoing financial challenges. The future outlook includes strategic initiatives to sustain growth, but foreign exchange fluctuations pose a potential risk.Company Guidance
During the Pulmonx Fourth Quarter 2024 Earnings Conference Call, the company provided guidance for 2025, emphasizing expected revenue growth between $96 million and $98 million, reflecting a 16% to 18% growth rate on a constant currency basis. The company anticipates gross margins to remain approximately 74%, improving in the second half due to higher production volumes, geographic mix, and cost optimization initiatives. Operating expenses for the year are projected to range from $133 million to $135 million, including $22 million in non-cash stock-based compensation. Pulmonx aims to scale its initiatives in the first half of 2025, driving a re-acceleration of U.S. growth in the second half, while strong international growth is expected in the first half, followed by typical seasonality. The company remains committed to sustainable long-term growth of at least 20%.Strong Revenue Growth
Pulmonx reported worldwide sales of $23.8 million in Q4 2024, reflecting 23% growth over the same period last year. Full year 2024 worldwide revenue was $83.8 million, representing 22% growth over 2023.
Record International Sales
Record international sales of $7.9 million in Q4 2024, representing 42% growth year-over-year. Strong performance in key European markets and successful expansion in China.
Expansion of U.S. Account Base
Expanded U.S. account base with 52 new centers in 2024, ending the year with 283 active accounts in Q4.
Notable Clinical Trials and Studies
Launched AeriSeal CONVERT II Pivotal Trial and Japanese post-market study. Demonstrated successful conversion of collateral ventilation status in 77.6% of patients in AeriSeal CONVERT Trial.
Innovation and Product Launches
Introduced LungTrax platform and new Chartis Precision Catheter. Launched first U.S. TV commercial reaching over 11 million people.
Positive Financial Metrics
Gross margin for fiscal year 2024 was 74%, consistent with 2023. Adjusted EBITDA loss improved by 10% in Q4 2024 and by 20% for the full year.
---
LUNG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LUNG Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 19, 2025 | $6.64 | $8.78 | +32.23% |
| Oct 30, 2024 | $6.79 | $6.25 | -7.95% |
| Jul 31, 2024 | $6.91 | $6.49 | -6.08% |
| May 01, 2024 | $7.72 | $9.38 | +21.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pulmonx Corporation (LUNG) report earnings?
Pulmonx Corporation (LUNG) is schdueled to report earning on May 06, 2025, TBA Not Confirmed.
What is Pulmonx Corporation (LUNG) earnings time?
Pulmonx Corporation (LUNG) earnings time is at May 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LUNG EPS forecast?
LUNG EPS forecast for the fiscal quarter 2025 (Q1) is -0.4.
---